4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 276,726 | 49,652 | N/A | N/A | N/A |
| Receivables | 1,486 | 978 | N/A | N/A | N/A |
| TOTAL | $282,656 | $52,508 | $N/A | $N/A | $N/A |
| Non-Current Assets | |||||
| PPE Net | 5,073 | 5,049 | N/A | N/A | N/A |
| Other Non-Current Assets | 602 | 677 | 0 | 0 | 0 |
| TOTAL | $5,675 | $5,726 | $N/A | $N/A | $N/A |
| Total Assets | $288,331 | $58,234 | $N/A | $N/A | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,787 | 1,744 | 0 | 0 | 0 |
| Accrued Expenses | 8,371 | 5,347 | N/A | N/A | N/A |
| TOTAL | $16,744 | $12,955 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | |||||
| Deferred Revenues | 6,586 | 5,864 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 1,974 | 104,646 | 0 | 0 | 0 |
| TOTAL | $15,200 | $118,249 | $N/A | $N/A | $N/A |
| Total Liabilities | $31,944 | $131,204 | $N/A | $N/A | $N/A |
| Shareholders' Equity | |||||
| Common Shares | 3 | 1 | N/A | N/A | N/A |
| Retained earnings | -135,679 | -79,025 | N/A | N/A | N/A |
| TOTAL | $256,387 | $-72,970 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $288,331 | $58,234 | $0 | $0 | $0 |